{"name": "Agennix",
 "permalink": "agennix",
 "crunchbase_url": "http://www.crunchbase.com/company/agennix",
 "homepage_url": "http://www.agennix.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": 1997,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@agennix.com",
 "phone_number": "+49 89 85 65 2600",
 "description": "",
 "created_at": "Tue Mar 23 02:34:26 UTC 2010",
 "updated_at": "Tue Mar 23 02:34:25 UTC 2010",
 "overview": "\u003Cp\u003EAgennix AG is a publicly traded biopharmaceutical company that is developing novel therapies in areas of major unmet medical need to improve the length and quality of life of seriously ill patients. The Company\u00e2\u20ac\u2122s most advanced program is talactoferrin, an oral targeted therapy that has demonstrated activity in randomized, double-blind, placebo-controlled Phase 2 studies in non-small cell lung cancer as well as in severe sepsis. Talactoferrin is currently in Phase 3 clinical trials in non-small cell lung cancer. Other clinical development programs include RGB-286638, a multi-targeted kinase inhibitor in Phase 1 testing; the oral platinum-based compound satraplatin; and a topical gel form of talactoferrin for diabetic foot ulcers. Agennix\u00e2\u20ac\u2122s registered seat is in Heidelberg, Germany. The Company has three sites of operation: Martinsried/Munich, Germany; Princeton, New Jersey and Houston, Texas.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       50],
      "assets/images/resized/0008/1317/81317v1-max-150x150.jpg"],
     [[225,
       76],
      "assets/images/resized/0008/1317/81317v1-max-250x250.jpg"],
     [[225,
       76],
      "assets/images/resized/0008/1317/81317v1-max-450x450.jpg"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$13M",
 "funding_rounds":
  [{"round_code": "unattributed",
    "source_url": "http://www.fiercebiotech.com/story/agennix-raises-13m-late-stage-cancer-trial/2010-03-22?utm_medium=rss\u0026utm_source=rss",
    "source_description": "Agennix raises $13M for late-stage cancer trial",
    "raised_amount": 13000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2010,
    "funded_month": 3,
    "funded_day": 22,
    "investments":
     []}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "Fraunhoferstrasse 20",
    "address2": "",
    "zip_code": "82152",
    "city": "Planegg",
    "state_code": null,
    "country_code": "DEU",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        99],
       "assets/images/resized/0008/1316/81316v1-max-150x150.jpg"],
      [[250,
        166],
       "assets/images/resized/0008/1316/81316v1-max-250x250.jpg"],
      [[450,
        299],
       "assets/images/resized/0008/1316/81316v1-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  []}